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Purpose or Objective: Conventionally in radiotherapy, a 
large beam forming apparatus is rotated around a stationary 
patient in order to achieve multiple beam angles. However, 
for a number of emerging and existing treatment modalities 
such as proton therapy, heavy ion therapy, MRI guided 
therapy, and synchrotron based therapies, such an approach 
results in prohibitively expensive and complex treatment 
systems. At the same time, much of the world has no access 
whatsoever to even conventional radiation therapy 
treatments. Replacing the gantry rotation with patient 
rotation could lead to much simpler and more cost effective 
treatment units. However, it is often assumed that patient 
acceptance would be a major barrier to widespread use of 
such a system. The purpose of this work was to test this 
assumption by investigating patient tolerance to slow single 
arc rotation. 
 
Material and Methods: The Epley Omniax (Figure 1) is a 
clinically approved medical device conventionally used in 
balance disorder therapy, and can rotate 360 degrees around 
each axis. We used this device to test patient tolerance to 
slow, single arc rotation. Each patient underwent slow, single 
arc rotation in two orientations; sitting and lying. Patients 
were rotated a full 360 degrees in increments of 45 degrees. 
The rotation was paused for 30 seconds at each 45 degree 
increment to simulate beam delivery; in total this simulates 
the delivery of 8 beams. Patients were rotated in both an 
upright (sitting) and lying position in the same session. 
Response was monitored via validated psychometric 
questionnaires for claustrophobia, anxiety, and motion 
sickness. Thus far, 10 of a planned 15 current or former 
cancer patients have been recruited. 
 
 
 
Results: Patient tolerance has been high – 9 out of 10 have 
completed the study without incident, and in general patient 
feedback has been positive. One patient was unable to 
complete the lying rotation, but was still able to complete 
the sitting rotation without issue. No detectible differences 
in anxiety or motion sickness have been observed from either 
sitting or lying rotation. A summary of the patient cohort and 
results thus far is outlined in table 1. Accrual for this study is 
ongoing. 
 
 
Conclusion: Patient rotation could enable much simpler 
treatment for both conventional and advanced treatments – 
however, it is often assumed that patient tolerance to 
rotation would be very low. The results generated thus far 
show that there is at least a cohort of patients who would 
find slow rotation an acceptable therapeutic intervention. 
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Purpose or Objective: Potential severe or lethal toxicity in 
regards to dose escalation of locally-advanced NSCLC patients 
calls for caution. A national quality assurance program was 
conducted over a period of three years in Denmark in order 
to prepare for the heterogeneous FDG-guided dose escalation 
phase 3 trial: NARLAL2. 
 
Material and Methods: A national work group consisting of 
clinical oncologists and medical physicists was established. 
Different workshops were conducted in order to standardise 
1) delineation of organs at risk (OAR) and target, 2) PET 
determination, 3) treatment planning, and 4) IGRT and 
adaptive strategy. In the standard arm, the planning target 
volume (PTV) is prescribed a homogeneous mean dose of 66 
Gy / 33 fractions (fr). For the experimental arm, the mean 
dose is heterogeneously escalated up to 95 Gy / 33 fr for the 
most FDG-PET active part of the primary tumour and 74 Gy / 
33fr for malignant lymph nodes ≥ 4 cc. The escalation is 
always limited in favour of OAR constraints. Dose constraints 
were added to reduce the risk of severe complications. 
Besides the traditional spinal cord, heart and oesophagus 
delineations, thorax wall, aorta, bronchi, trachea, and 
connective tissue (here defined as any remaining voxels in 
mediastinum not included in other OARs or GTV) were 
delineated. A maximum dose of D1cc < 74 Gy for these OARs 
was chosen as safe dose constraints (D1cc < 70 Gy for 
oesophagus). An online catalogue with examples of such 
delineations was created for oncologists. The randomisation 
is performed when both the standard and escalated plans are 
clinically accepted. The two treatment plans, delineations 
and images are prospectively exported to a national 
database, which requires a consistent naming convention for 
delineations within each centre. Endpoint of trial is local 
control and the standard procedure for suspicion of tumour 
recurrence is biopsy. For cases where biopsy is not 
applicable, a central committee has been established to 
evaluate each case. Blood samples are obtained during the 
treatment course for future examination. 
